VADS Are Ready For Wider Population Trial After REMATCH, Experts Agree
This article was originally published in The Gray Sheet
Executive SummaryThe high complication rate associated with Thoratec's HeartMate VE ventricular assist device (VAD) in the seminal REMATCH trial should not deter investigators from testing VADs as a destination therapy in patients less ill than the REMATCH cohort, panelists agreed at an April 10 symposium on trials of mechanical circulatory support in Washington, DC
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.